Tags

Type your tag names separated by a space and hit enter

Hemoglobin-based oxygen carrier (HBOC-201) and escalating doses of recombinant factor VIIa (rFVIIa) as a novel pre-hospital resuscitation fluid in a swine model of severe uncontrolled hemorrhage.

Abstract

Exsanguinating hemorrhage and unavailability of blood are major problems in pre-hospital trauma care. We investigated if combining rFVIIa with HBOC-201 reduces blood loss and improves physiologic parameters compared to HBOC alone. Swine underwent liver injury and were resuscitated with HBOC-201 alone or HBOC+90, 180 or 360 μg/kg rFVIIa before hospital arrival at 240 min; animals survived to 72 hours. Blood loss was reduced; MAP, CI, transcutaneous oxygen saturation, and 72-hour survival improved in the 90 and 180 μg/kg rFVIIa groups. Lactate was cleared faster in the HBOC+rFVIIa 90 μg/kg group. Verification in a large, well-powered study is indicated.

Authors+Show Affiliations

Operational and Undersea Medicine Directorate, NeuroTrauma Department, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA. anke.scultetus@med.navy.milNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

20645681

Citation

Scultetus, Anke, et al. "Hemoglobin-based Oxygen Carrier (HBOC-201) and Escalating Doses of Recombinant Factor VIIa (rFVIIa) as a Novel Pre-hospital Resuscitation Fluid in a Swine Model of Severe Uncontrolled Hemorrhage." Artificial Cells, Blood Substitutes, and Immobilization Biotechnology, vol. 39, no. 2, 2011, pp. 59-68.
Scultetus A, Arnaud F, Kaplan L, et al. Hemoglobin-based oxygen carrier (HBOC-201) and escalating doses of recombinant factor VIIa (rFVIIa) as a novel pre-hospital resuscitation fluid in a swine model of severe uncontrolled hemorrhage. Artif Cells Blood Substit Immobil Biotechnol. 2011;39(2):59-68.
Scultetus, A., Arnaud, F., Kaplan, L., Shander, A., Philbin, N., Rice, J., McCarron, R., & Freilich, D. (2011). Hemoglobin-based oxygen carrier (HBOC-201) and escalating doses of recombinant factor VIIa (rFVIIa) as a novel pre-hospital resuscitation fluid in a swine model of severe uncontrolled hemorrhage. Artificial Cells, Blood Substitutes, and Immobilization Biotechnology, 39(2), 59-68. https://doi.org/10.3109/10731199.2010.501755
Scultetus A, et al. Hemoglobin-based Oxygen Carrier (HBOC-201) and Escalating Doses of Recombinant Factor VIIa (rFVIIa) as a Novel Pre-hospital Resuscitation Fluid in a Swine Model of Severe Uncontrolled Hemorrhage. Artif Cells Blood Substit Immobil Biotechnol. 2011;39(2):59-68. PubMed PMID: 20645681.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hemoglobin-based oxygen carrier (HBOC-201) and escalating doses of recombinant factor VIIa (rFVIIa) as a novel pre-hospital resuscitation fluid in a swine model of severe uncontrolled hemorrhage. AU - Scultetus,Anke, AU - Arnaud,Francoise, AU - Kaplan,Lewis, AU - Shander,Aryeh, AU - Philbin,Nora, AU - Rice,Jennifer, AU - McCarron,Richard, AU - Freilich,Daniel, Y1 - 2010/07/20/ PY - 2010/7/22/entrez PY - 2010/7/22/pubmed PY - 2011/6/16/medline SP - 59 EP - 68 JF - Artificial cells, blood substitutes, and immobilization biotechnology JO - Artif Cells Blood Substit Immobil Biotechnol VL - 39 IS - 2 N2 - Exsanguinating hemorrhage and unavailability of blood are major problems in pre-hospital trauma care. We investigated if combining rFVIIa with HBOC-201 reduces blood loss and improves physiologic parameters compared to HBOC alone. Swine underwent liver injury and were resuscitated with HBOC-201 alone or HBOC+90, 180 or 360 μg/kg rFVIIa before hospital arrival at 240 min; animals survived to 72 hours. Blood loss was reduced; MAP, CI, transcutaneous oxygen saturation, and 72-hour survival improved in the 90 and 180 μg/kg rFVIIa groups. Lactate was cleared faster in the HBOC+rFVIIa 90 μg/kg group. Verification in a large, well-powered study is indicated. SN - 1532-4184 UR - https://www.unboundmedicine.com/medline/citation/20645681/Hemoglobin_based_oxygen_carrier__HBOC_201__and_escalating_doses_of_recombinant_factor_VIIa__rFVIIa__as_a_novel_pre_hospital_resuscitation_fluid_in_a_swine_model_of_severe_uncontrolled_hemorrhage_ L2 - https://www.tandfonline.com/doi/full/10.3109/10731199.2010.501755 DB - PRIME DP - Unbound Medicine ER -